Eur J Gastroenterol Hepatol. 2018 Sep 1. doi: 10.1097/MEG.0000000000001254. [Epub ahead of print]
Effects of antiviral treatment on the risk of hepatocellular cancer in patients with chronic viral hepatitis.
Stournaras E1, Neokosmidis G, Stogiannou D, Protopapas A, Tziomalos K.
Author information
1
First Propaedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece.
Abstract
Hepatocellular carcinoma (HCC) is a major complication of chronic hepatitis B (CHB) and chronic hepatitis C (CHC). Accumulating data suggest that antiviral treatment in both CHB and CHC reduces the incidence of HCC. Evidence is more consistent for interferon-based treatment in both CHB and CHC and for lamivudine in patients with CHB. However, more limited data suggest that other nucleos(t)ide analogues might also reduce the risk of HCC. In contrast, conflicting data have been reported on the effects of direct-acting antivirals on the incidence of HCC.